Kalaris Therapeutics Inc KLRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.49
- Day Range
- $4.33–4.54
- 52-Week Range
- $2.14–11.88
- Bid/Ask
- $3.04 / $6.90
- Shares Outstanding
- 23.79M
- Market Cap
- $105.64M
- Volume/Avg
- 10,279 / 83,847
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 20
- Website
- https://www.kalaristx.com
Valuation
|
Metric
|
KLRS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KLRS
|
|---|---|
Quick Ratio | 12.03 |
Current Ratio | 12.19 |
Interest Coverage | — |
Quick Ratio
KLRS
Profitability
|
Metric
|
KLRS
|
|---|---|
Return on Assets (Normalized) | −41.06% |
Return on Equity (Normalized) | −68.20% |
Return on Invested Capital (Normalized) | −67.23% |
Return on Assets
KLRS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|X%S%y?^ | LOCK|$c>&D | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Q>R#y$ | LOCK|$!KcW | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&K@r>@ | LOCK|C< | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|HhR#yd? | LOCK|D?xm | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|qdv&mq | LOCK|?rJ | $36B | |||
| Moderna Inc
MRNA
| LOCK|Kk@%!% | LOCK|>S | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X%<dBz?j | LOCK|!%f! | $25B | |||
| Incyte Corp
INCY
| LOCK|!fX@km? | LOCK|kwd | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|h%?#Sc | LOCK|R> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<@>nr$s | LOCK|J?% | $17B |
United States